Residues of pharmaceuticals in natural and treated waters have become a significant public health and environmental concern. Substances such as antibiotics, antidepressants, beta-blockers, and oral contraceptives, after being consumed by humans, eventually find their way into rivers, lakes, groundwater, and even water intended for human consumption. This contamination, stemming from the inability of water treatment systems to completely filter out these chemical compounds, has detrimental consequences for aquatic ecosystems and, in the long term, for human health.
Between 30% and 90% of the medications we take orally, such as antibiotics, hormones, and painkillers, are excreted into the environment as unmetabolized active substances. These residues enter wastewater systems and eventually spread into waterways and soils, where they negatively impact aquatic organisms. Fish and amphibians, in particular, suffer devastating effects on their internal organs and reproductive cycles, jeopardizing their survival and disrupting the ecosystems they are an integral part of. Studies have shown that these pharmaceutical residues can alter the growth, reproduction, and behavior of these species, triggering cascading effects on aquatic biodiversity.
While the healthcare sector is a critical pillar of society, it also generates significant environmental externalities. Estimates suggest it accounts for 4.4% of global carbon dioxide (CO₂) emissions, underscoring the urgency of finding solutions to mitigate the ecological footprint of pharmaceutical production and management. To address this, engineers and researchers are actively developing water treatment technologies to reduce the presence of these residues in the environment.
Example of the Swedish system
In Uppsala, Sweden, an innovative pilot project focuses on removing at least 80% of five particularly harmful pharmaceutical substances. Various methods are being tested, including the use of activated carbon and anion exchange, two promising technologies for filtering and absorbing chemical residues. These solutions are being evaluated not only for their effectiveness but also for their cost, to ensure their viability in wastewater treatment plants of different sizes and geographical contexts.
The timeline is tight: the pilot project is scheduled to conclude by 2024. This deadline reflects the urgency of improving pharmaceutical residue removal technologies in Sweden and worldwide. The outcomes of this project could serve as a model for other regions seeking to address water contamination by pharmaceutical residues. Developing cost-effective and efficient removal methods is crucial to protecting aquatic biodiversity and preventing potential health risks associated with exposure to these substances in drinking water.
The potential benefits of this pilot project are vast. In addition to preserving aquatic flora and fauna, it would help mitigate health risks linked to the presence of pharmaceutical residues in drinking water. Given the scale of the ecological and health challenges, such technological innovations could become a standard in water resource management, ensuring a safer and healthier future for generations to come.
Country survey on the number of pharmaceutical substances detected in surface water, groundwater, or tap/drinking water (aus des beck et al 2016)
Sources :
OFB
Pharmaceuticals in the environment–Global occurrences and perspectives
Tim aus der Beek 1, Frank-Andreas Weber 1, Axel Bergmann 1, Silke Hickmann 2, Ina Ebert 2, Arne Hein 2, Anette Küster 2
